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ABSTRACT
Purpose. Pretransplant obesity is a well-known risk fac-
tor for post-transplant outcomes such as patient and 
graft survival, delayed graft function, rejection, and 
wound complications. According to the recommen-
dations of the European Renal Best Practice, patients 
who have body mass index (BMI) value of more than 
30 kg/m2 before kidney transplantation should reduce 
their weight. 
Materials and methods. In the group of 297 patients 
who had undergone primary kidney transplantation 
from post-mortem donors, we found that assessed 
the impact of BMI on the development of new onset 
diabetes after transplantation (NODAT). Additionally, 
relationships between immunosuppression, weight 
gain and BMI in patients after kidney transplantation 
were also analysed. We measured the value of the pa-
tients’ BMI and weight before kidney transplantation, 
12 months after kidney transplantation, and 5 years 
after kidney transplantation. The group contained 
only those patients who, at the time of the kidney 
transplantation, did not suffer from diabetes mel-
litus. According to the development of NODAT in the 
monitored period, the group of patients was divided 
into the control group and NODAT group. We detected 
analysed the data on the type of immunosuppression 
(tacrolimus, cyclosporine A, mTOR inhibitor) and the 
average levels in the monitored period and identified 
whether BMI or increased weight 12 months and 5 
years after kidney transplantation is related to the level 
(or dose) of the used immunosuppression.
Results. In our group, the patients who developed 
NODAT in the post-transplant period were significantly 
older in the 12-month analysis (p < 0.0001) and also in 
the 5-year analysis (p = 0.0001); had higher BMI at the 
time of transplantation (p = 0.0003) and higher BMI 
12 months after kidney transplantation (p = 0.0004) 
and a significantly higher weight gain 12 months after 
kidney transplantation (p = 0.0469). We discovered 
that neither the level of immunosuppression nor the 
dose of prednisone had any effect on the increase in 
BMI or weight gain during the monitored period.
Conclusion. The patients in the waiting list, who 
have any risk factors for the development of diabetes 
mellitus, should be informed how to eliminate these 
risk factors (weight control, diet, physical exercises, 
etc.). In addition to the above, all candidates for 
kidney transplantation are recommended to stop 
smoking, to control blood pressure, and perform 
a lipidogram. (Clin Diabet 2016; 5, 1: 1–6)
Key words: body mass index, immunosuppression, 
NODAT, kidney transplantation
Introduction
The risk factors of cardiovascular diseases are elimi-
nated after kidney transplantation by the recovery of 
renal function. However, new risks factors occur at the 
same time, such as impaired glucose tolerance, diabetes 
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mellitus, arterial hypertension, lipid metabolism disorders, 
and other issues. The newly diagnosed diabetes mellitus 
after transplantation (NODAT) represents a serious and 
frequent complication in the transplantation of solid or-
gans. The incidence varies from 4% to 25%, depending 
on the transplanted organ, the duration of monitoring of 
the patient, and the used immunosuppression protocol 
[1–4]. Risk factors for NODAT are shown in Table 1.
The risk of cardiovascular (CVS) diseases in patients 
with NODAT is increased also by hyperlipoproteinaemia, 
arterial hypertension, or smoking. NODAT is connected 
also with other complications, namely: rejection of the 
graft, recurring infections, and worse long-term func-
tion of the graft [5, 6].
Pretransplant obesity is a well-known risk factor 
for post-transplant outcomes such as patient and 
graft survival, delayed graft function, rejection, and 
wound complications [7–11]. Several recent studies 
have shown that significant post-transplant weight 
gain is also a risk factor for the patient and for graft 
survival. Identifying patients at high risk of significant 
post-transplant weight gain and using various methods 
to help control their body weight may improve the 
patient and the graft survival [12–14]. 
According to the recommendations of the Euro-
pean Renal Best Practice (ERBP), patients with a body 
mass index (BMI) value of more than 30 kg/m2 before 
kidney transplantation should reduce their weight. 
There is uncertainty regarding the relationship 
between obesity and outcomes after kidney transplan-
tation. Obese kidney transplant recipients may have 
poorer outcomes compared with non-obese recipients; 
however, the outcomes may be better compared with 
patients who remain on dialysis. There is no consensus 
on whether obesity should be an exclusion criterion for 
kidney transplantation, and the policies differ among 
transplant centres [15, 16].
Materials and methods
In the group of 297 patients (of Central European 
origin) who had undergone primary kidney trans-
plantation from post-mortem donors (in the years 
2003–2014) at the Transplantation Center in Martin, 
we measured their body mass index value and weight 
before kidney transplantation, 12 months and 5 years 
after kidney transplantation. The aim of the study was 
to determine the impact of BMI on the development 
of NODAT and relationships between immunosuppres-
sion level and weight gain and BMI in patients after 
kidney transplantation. The group included only those 
patients who, at the time of kidney transplantation, 
did not suffer from diabetes mellitus. According to 
development of NODAT in the monitored period, the 
group of patients was divided into the control group 
and the NODAT group. NODAT was diagnosed ac-
cording to the American Diabetes Association’s (ADA) 
criteria. The individually monitored parameters were 
compared in both groups. Furthermore, we noted the 
type of immunosuppression (tacrolimus, cyclosporine 
A, mTOR inhibitor), the average levels of immunosup-
pressive drugs, and the average dose of prednisone in 
the monitored period. By the correlation coefficient, 
we identified whether BMI or weight gain 12 months 
and 5 years after kidney transplantation is related to 
the level (or dose) of the used immunosuppression. In 
the statistical evaluation, we used the certified statistics 
program MedCalc version 13.1.2 and the following sta-
tistical analyses: student’s t-test, chi-quadrate test, and 
correlation coefficient. We found the value of p < 0.05 
to be statistically significant.
Results
The group was composed of 297 patients who 
had undergone primary kidney transplantation from 
post-mortem donors and who were included in the 
Table 1. Risk factors for NODAT development [5]
Non-modifiable risk factors for NODAT Modifiable risk factors for NODAT
Age at the time of transplantation Immunosuppression (corticosteroids, CNIs, mTOR inhibitors)
Population (Afro-Americans, Hispanics) Obesity
Positive family history of DM2 Hypertriacylglycerolaemia
Male gender Artery hypertension
HLA A30, B27, B42 Hypomagnesemia
Higher number of HLA mismatches Prediabetes before transplantation
Polycystic kidney disease Viral hepatitis C
Cytomegalovirus infection
Basiliximab in induction
Proteinuria
DM2 — diabetes mellitus type 2; CNI — calcineurin inhibitor; mTOR — mammalian target of rapamycin
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12-month analysis, and 182 patients who had received 
a kidney transplant 5 years ago (5-year analysis). The 
data were collected on the presence of polycystic 
kidney disease as a cause of kidney failure, as well as 
the presence of hypertension and a family history of 
type 2 diabetes (parents, siblings, and grandparents). 
The mean levels of tacrolimus in the control group 
was 4.7 ± 0.9 ng/mL; in the NODAT group it was 4.8 ± 
± 1.2 ng/mL (p = 0.5592). The mean cyclosporin A 
levels in the control group was 86.9 ± 44.6 ng/mL; in 
the NODAT group it was 96 ± 10.7 ng/mL (p = 0.7946). 
Mean sirolimus levels in the control group was 6.8 ± 
± 0.7 ng/mL; in the NODAT group it was 6.7 ± 0.5 ng/mL 
(p = 0.7210). Average daily dose of prednisone in the 
control group, was 8.2 ± 2.3 mg/day and in the NODAT 
group it was 8.8 ± 2.0 mg/day (p = 0.1734).
12-month analysis
The average age of the patients at the time of kid-
ney transplantation (n = 297) was 47.4 ± 13.2 years. 
The group comprised 187 males (63%) and 110 females 
(37%). There were 178 patients (59.9%) with the aver-
age age of 43.7 ± 12.8 years in the control group. NO-
DAT in the monitored period developed in 119 patients 
(40.1%) with the average age of 51.1 ± 13.6 years 
(p < 0.0001). The value of BMI at the time of trans-
plantation in the entire group was 24.9 ± 4.9 kg/m2. 
The value of BMI 12 months after kidney transplantation 
was 27.8 ± 4.9 kg/m2. The average value of BMI before 
kidney transplantation in the control group was 23.8 
± 4.7 kg/m2, and in the NODAT group it was 25.9 ± 
± 5.1 kg/m2 (p = 0.0003). The value of BMI 12 months 
after kidney transplantation in the control group 
was 26.7 ± 5 kg/m2, and in the NODAT group it was 
28.8 ± 4.9 kg/m2 (p = 0.0004). The average weight 
gain 12 months after kidney transplantation in the 
entire group was 5.5 ± 5.2 kg, in the control group 
it was 4.9 ± 4.7 kg, and in the NODAT group it was 
6.1 ± 5.6 kg (p =0.0469). Polycystic kidney disease 
as a cause of renal failure was present in 10.4% of 
the control group and in 17.2% of the NODAT group 
(p = 0.2839). Arterial hypertension was diagnosed in 
99.4% of the control group and 100% of the NODAT 
group (p = 0.8866). Positive family history for NODAT 
in the control group was present in 33.7% and in the 
NODAT group it was present in 50.4% (0.0059).
5-year analysis
The average age of the patients at the time of 
kidney transplantation (n = 182) was 48 ± 13 years. 
There were 106 patients (58.2%) with the average age 
of 44.1 ± 12.2 years in the control group. NODAT in 
the monitored period developed in 76 patients (41.8%) 
with the average age 51.9 ± 13.8 years (p = 0.0001). 
The value of BMI 5 years after kidney transplantation in 
the control group was 27.9 ± 5.1 kg/m2. In the NODAT 
group it was 29.5 ± 6.4 kg/m2 (p = 0.0624). The aver-
age weight gain5 years after kidney transplantation 
in the entire group was 9.4 ± 8.7 kg, in the control 
group it was 8.6 ± 7.7 kg, and in the NODAT group 
it was 10.2 ± 9.7 kg (p = 0.2169) (see Tab. 1). By the 
correlation coefficient, we discovered that the average 
level of immunosuppression (tacrolimus, cyclosporine 
A, mTOR inhibitor, or the dose of prednisone) was 
not related to the BMI value and the increased weight 
(see Tab. 3–7).
Discussion
In our group, the patients who developed NODAT 
in the post-transplantation period were significantly 
older (both in the 12-month and the 5-year analysis), 
had higher BMI at the time of transplantation, higher 
Table 2. Characteristics of the group
12-month analysis Control group (n = 178) NODAT (n = 119) P value
Age at the time of transplantation (years) 43.7 ± 12.8 51.1 ± 13.6 < 0.0001
ADPKD (%) 10,4 17.2 0.839
Arterial hypertension (%) 99.4 100 0.8866
Positive family history of DM2 (%) 33.7 50.4 0.0059
BMI at the time of transplantation [kg/m2] 23.8 ± 4.7 25.9 ± 5.1 0.0003
BMI 12 months after transplantation [kg/m2] 26.7 ± 5 28.8 ± 4.9 0.0004
Weight gain 12 months from transplantation 4.9 ± 4.7 6.1 ± 5.6 0.0469
5-year analysis Control group (n = 106) NODAT (n = 76) P value
Age at the time of transplantation (years) 44.1 ± 12.2 51.9 ± 13.8 0.0001
BMI 5 years after transplantation [kg/m2] 27.9 ± 5.1 29.5 ± 6.4 0.0624
Weight gain 5 years after transplantation [kg] 8.6 ± 7.7 10.2 ± 9.7 0.2169
ADPKD — polycystic kidney disease; DM2 — diabetes mellitus type 2
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BMI 12 months after kidney transplantation, and sig-
nificantly higher weight gain 12 months after kidney 
transplantation. 
According to other studies, which agree with our 
study, the age at the time of kidney transplantation 
is considered to be an independent risk factor for the 
development of NODAT. Cosio et al. found a 2.2 times 
higher risk of the development of NODAT in recipients 
older than 45 years of age, compared to younger recipi-
ents [17]. The USRDS data show a strong relationship 
between the recipient’s age and the development of 
NODAT. The recipients at the age of 45–59 years had 
a 1.9 times higher risk of the development of NODAT 
compared with recipients in the age of 18–33 years. 
In the recipients older than 60 years, the risk of the 
development of NODAT was 2 times higher than in the 
younger recipients [18]. 
Obesity before transplantation (defined as BMI 
> 30 kg/m2) increases the risk of losing the graft. After 
transplantation, it increases the risk of cardiovascular 
diseases [19, 20]. Weight gain is almost a rule in the 
patients after transplantation [21, 22]. According to 
the IDF criteria for metabolic syndrome, the waist 
circumference is the basic parameter. Obesity of po-
tential recipients before transplantation is a frequent 
finding. A BMI value of more than 35 kg/m2 represents 
a contraindication for kidney transplantation, and 
a BMI the value of 33–35 kg/m2 represents a relative 
contraindication for transplantation, with necessary 
pretransplantation examination by a surgeon. Higher 
BMI values before transplantation are connected with 
insulin resistance after transplantation, and education 
of the patients on reduction of their weight before 
transplantation gives the opportunity for reduced 
risk of the development of NODAT and cardiovascular 
diseases [23–25].
In our group, we did not record any effect of the 
level of the used immunosuppression or the dose of 
prednisone on the BMI values after transplantation. 
An interesting finding in our analysis is the fact 
that the levels of the used immunosuppression have 
no effect on increased BMI neither 12 months nor 
5 years after kidney transplantation. Tacrolimus inhibits 
the reversible suppression of the secretion of insulin in 
the level of transcription of mRNA insulin by binding 
to the FK506 binding protein-12, which leads to sub-
sequent inhibition of calcineurin in pancreas B-cells. 
A high concentration of FK506 binding protein-12 in 
pancreas may explain why tacrolimus inhibits secre-
tion of insulin in higher rates than cyclosporine A. 
Table 3. Correlation between BMI 12 months after transplantation and average level of immunosuppression
BMI 12 months after transplantation Correlation coefficient r 95% confidence interval for r P value
Level of tacrolimus 0.06254 –0.2816 to 0.3924 0.7253
Level of cyclosporine A 0.1087 –0.7709 to 0.8457 0.8375
Level of mTOR inhibitor 0.09117 –0.8603 to 0.9010 0.8841
Dose of prednisone 0.07241 –0.08271 to 0.2241 0.3598
Table 4. Correlation between BMI 5 years after transplantation and average level of immunosuppression
BMI 5 years after transplantation Correlation coefficient r 95% confidence interval for r P value
Level of tacrolimus –0.1283 –0.4471 to 0.2194 0.4697
Level of cyclosporine A –0.4138 –0.9494 to 0.7379 0.4886
Level of mTOR inhibitor 0.3909 –0.7500 to 0.9467 0.5152
Dose of prednisone –0.04342 –0.1968 to 0.1120 0.5844
Table 5. Correlation between weight gain 12 months after transplantation and average level of immunosuppression
Weight gain 12 months after transplantation Correlation coefficient r 95% confidence interval for r P value
Level of tacrolimus 0.09826 –0.1241 to 0.3113 0.3859
Level of cyclosporine A 0.1160 –0.7678 to 0.8478 0.8267
Level of mTOR inhibitor 0.3849 –0.7531 to 0.9459 0.5223
Dose of prednisone –0.09038 –0.2412 to 0.06472 0.2527
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Table 6. Correlation between weight gain 5 years after transplantation and average level of immunosuppression
Weight gain 5 years after transplantation Correlation coefficient r 95% confidence interval for r P value
Level of tacrolimus 0.1482 –0.07394 to 0.3563 0.1896
Level of cyclosporine A 0.3949 –0.7480 to 0.9472 0.5106
Level of mTOR inhibitor –0.9552 –0.9971 to –0.4642 0.1013
Dose of prednisone 0.04812 –0.1064 to 0.2004 0.5418
Our finding is supported also by the study by Rodri-
guez-Rodriguez et al. who confirm that the inhibitors 
of calcineurin have no effect on the patient’s weight; 
however, the pro-diabetogenic effect related to this is 
visible particularly in patients who had insulin resis-
tance already before transplantation [26]. Similarly, in 
regard to the level of immunosuppression, the dose of 
prednisone has no effect on increased BMI or weight 
gain. Based on the above findings, we may say that the 
patient’s diet had a clear effect on weight after kidney 
transplantation. 
Conclusion 
In our group, we identified BMI and weight gain as 
the risk factors for NODAT both in the 12-month and 
the 5-year analysis. Screening of the risk factors for 
development of diabetes mellitus should be performed 
before inserting the patient in the waiting list. It is 
also recommended to perform oral glucose tolerance 
test (OGTT) in patients with normal fasting glycaemia. 
Therefore, patients on the waiting list who have risk 
factors for the development of diabetes mellitus should 
be informed about the elimination of these risk factors 
(weight control, diet, physical exercises, etc.). In addi-
tion to the above, standard recom mendations to all 
candidates for kidney transplant include the following: 
to stop smoking, to control blood pressure, and to 
perform a lipidogram.
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